(Q91705195)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

title

Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

0 references

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

author name string

Shuting Shi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Haoru Zhu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Xinyu Xia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Zhihui Liang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Xuehu Ma

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

publication date

29 April 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

issue

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

page(s)

3167-3178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

Calcium phosphate: a substitute for aluminum adjuvants?

24 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

INSOLUBLE PRECIPITATES IN DIPHTHERIA AND TETANUS IMMUNIZATION.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Nanomaterial-Based Vaccine Adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Tailoring inorganic nanoadjuvants towards next-generation vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Mechanisms of action of adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Antigen depot is not required for alum adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Stability of aluminium-containing adjuvants during aging at room temperature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Mechanisms of stimulation of the immune response by aluminum adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

NLRP3 inflammasome activation induced by engineered nanomaterials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Enhanced Immune Adjuvant Activity of Aluminum Oxyhydroxide Nanorods through Cationic Surface Functionalization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

A role for impaired regulatory T cell function in adverse responses to aluminum adjuvant-containing vaccines in genetically susceptible individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

The history of MF59(®) adjuvant: a phoenix that arose from the ashes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Antigenicity of Soluble Protein in the Presence of High Levels of Antibody : a Possible Mode of Action of the Antigen Adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

The mechanism of action of MF59 - an innately attractive adjuvant formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Particle-based platforms for malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

CpG motifs in bacterial DNA trigger direct B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

CpG DNA as a vaccine adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Development of the CpG Adjuvant 1018: A Case Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Immunotherapeutic uses of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Adjuvants for human vaccines--current status, problems and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Liposomes as immunological adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Cation Permeability of Phospholipid Model Membranes: Effect of Narcotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Taking toll: lipid A mimetics as adjuvants and immunomodulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Lipopolysaccharide endotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Advances in saponin-based adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Saponins as cytotoxic agents: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Pathogen recognition in the innate immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Role of IL-15 in immune-mediated and infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Calcium phosphate nanoparticle adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Vaccine adjuvants: putting innate immunity to work

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Polysaccharides as vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Virosomal adjuvanted antigen delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Influenza virosomes as a vaccine adjuvant and carrier system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

PolyICLC Exerts Pro- and Anti-HIV Effects on the DC-T Cell Milieu In Vitro and In Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Polysaccharides: Candidates of promising vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Alum/Toll-Like Receptor 7 Adjuvant Enhances the Expansion of Memory B Cell Compartment Within the Draining Lymph Node.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

Eosinophil Response to Alum Adjuvants: Involvement of T Cells in Non-Antigen-Dependent Mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2019.04.055

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2019.04.055

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31047671%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

1 reference